1025MO Preliminary safety, pharmacokinetics and immunomodulatory activity of RBS2418, an oral ENPP1 inhibitor, alone and in combination with pembrolizumab in patients with solid tumors
Authors:
- T.U. MarronTMT.U. Marron
- J.G. MislehJMJ.G. Misleh
- C. ChenCCC. Chen
- Z.A. WainbergZWZ.A. Wainberg
- J. PowderlyJPJ. Powderly
- R. BocciaRBR. Boccia
- M. GordonMGM. Gordon
- J. SegarJSJ. Segar
- I. CsikiICI. Csiki
- J.M. SchanzerJSJ.M. Schanzer
- L. O'TOoleLOL. O'TOole
- N. HuangNHN. Huang
- 20 October 2023
- journal article
- abstracts
- Published by Elsevier in Annals of Oncology
- Vol. 34, S623-S624